J Cancer 2016; 7(11):1565-1570. doi:10.7150/jca.14582 This issue Cite

Review

Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response

Jill S Gluskin1, Fabrizio Chegai2✉, Serena Monti3, Ettore Squillaci2, Lorenzo Mannelli1

1. Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, C276, New York, NY 10065, USA.
2. Department of Diagnostic and Molecular Imaging, Radiation Therapy and Interventional Radiology, University Hospital Tor Vergata, Viale Oxford 81, 00133, Rome, Italy.
3. IRCCS Fondazione SDN spa , Naples, Italy.

Citation:
Gluskin JS, Chegai F, Monti S, Squillaci E, Mannelli L. Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response. J Cancer 2016; 7(11):1565-1570. doi:10.7150/jca.14582. https://www.jcancer.org/v07p1565.htm
Other styles

File import instruction

Abstract

Differentiating between cancerous tissue and healthy liver parenchyma could represent a challenge with the only conventional Magnetic Resonance (MR) imaging. Diffusion weighted imaging (DWI) exploits different tissue characteristics to conventional Magnetic Resonance Imaging (MRI) sequences that enhance hepatocellular carcinoma (HCC) detection, characterization, and post-treatment evaluation. Detection of HCC is improved by DWI, infact this technology increases conspicuity of lesions that might otherwise not be identified due to obscuration by adjacent vessels or due to low contrast between the lesion and background liver. It is important to remember that DWI combined with contrast-enhanced MRI has higher sensitivity than DWI alone, and that some patients are not eligible for use of contrast on CT and MRI; in these patients DWI has a prominent role. MRI has advanced beyond structural anatomic imaging to now showing pathophysiologic processes. DWI is a promising way to characterize lesions utilizing the inherent contrast within the liver and has the benefit of not requiring contrast injection. DWI improves detection and characterization of HCC. Proposed clinical uses for DWI include: assessing prognosis, predicting response, monitoring response to therapy, and distinguishing tumor recurrence from treatment effect. Ideally, DWI will help risk stratify patients and will participate in prognostic modeling.

Keywords: Hepatocellular Carcinoma, Diffusion weighted imaging (DWI), Hepatic carcinogenesis.


Citation styles

APA
Gluskin, J.S., Chegai, F., Monti, S., Squillaci, E., Mannelli, L. (2016). Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response. Journal of Cancer, 7(11), 1565-1570. https://doi.org/10.7150/jca.14582.

ACS
Gluskin, J.S.; Chegai, F.; Monti, S.; Squillaci, E.; Mannelli, L. Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response. J. Cancer 2016, 7 (11), 1565-1570. DOI: 10.7150/jca.14582.

NLM
Gluskin JS, Chegai F, Monti S, Squillaci E, Mannelli L. Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response. J Cancer 2016; 7(11):1565-1570. doi:10.7150/jca.14582. https://www.jcancer.org/v07p1565.htm

CSE
Gluskin JS, Chegai F, Monti S, Squillaci E, Mannelli L. 2016. Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response. J Cancer. 7(11):1565-1570.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image